Skip to content

Dexcom

NASDAQ: DXCM · USD

Dexcom financials

6 charts

Revenue

USD millions

$1,308.4M
Dexcom Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2011 Q2$21.417M; Change unavailable vs FY 2011 Q1
FY 2011 Q3$18.254M; −14.8% vs FY 2011 Q2
FY 2011 Q4$22.421M; +22.8% vs FY 2011 Q3
FY 2012 Q1$20.095M; −10.4% vs FY 2011 Q4
FY 2012 Q2$23.45M; +16.7% vs FY 2012 Q1
FY 2012 Q3$23.089M; −1.5% vs FY 2012 Q2
FY 2012 Q4$33.3M; +44.2% vs FY 2012 Q3
FY 2013 Q1$29.6M; −11.1% vs FY 2012 Q4
FY 2013 Q2$35.8M; +20.9% vs FY 2013 Q1
FY 2013 Q3$42.9M; +19.8% vs FY 2013 Q2
FY 2013 Q4$51.7M; +20.5% vs FY 2013 Q3
FY 2014 Q1$47.1M; −8.9% vs FY 2013 Q4
FY 2014 Q2$58.8M; +24.8% vs FY 2014 Q1
FY 2014 Q3$69M; +17.3% vs FY 2014 Q2
FY 2014 Q4$84.3M; +22.2% vs FY 2014 Q3
FY 2015 Q1$72.8M; −13.6% vs FY 2014 Q4
FY 2015 Q2$93.2M; +28.0% vs FY 2015 Q1
FY 2015 Q3$105.2M; +12.9% vs FY 2015 Q2
FY 2015 Q4$130.8M; +24.3% vs FY 2015 Q3
FY 2016 Q1$116.2M; −11.2% vs FY 2015 Q4
FY 2016 Q2$137.3M; +18.2% vs FY 2016 Q1
FY 2016 Q3$148.6M; +8.2% vs FY 2016 Q2
FY 2016 Q4$171.2M; +15.2% vs FY 2016 Q3
FY 2017 Q1$142.3M; −16.9% vs FY 2016 Q4
FY 2017 Q2$170.6M; +19.9% vs FY 2017 Q1
FY 2017 Q3$184.6M; +8.2% vs FY 2017 Q2
FY 2017 Q4$221M; +19.7% vs FY 2017 Q3
FY 2018 Q1$184.4M; −16.6% vs FY 2017 Q4
FY 2018 Q2$242.5M; +31.5% vs FY 2018 Q1
FY 2018 Q3$266.7M; +10.0% vs FY 2018 Q2
FY 2018 Q4$338M; +26.7% vs FY 2018 Q3
FY 2019 Q1$280.5M; −17.0% vs FY 2018 Q4
FY 2019 Q2$336.4M; +19.9% vs FY 2019 Q1
FY 2019 Q3$396.3M; +17.8% vs FY 2019 Q2
FY 2019 Q4$462.8M; +16.8% vs FY 2019 Q3
FY 2020 Q1$405.1M; −12.5% vs FY 2019 Q4
FY 2020 Q2$451.8M; +11.5% vs FY 2020 Q1
FY 2020 Q3$500.9M; +10.9% vs FY 2020 Q2
FY 2020 Q4$568.9M; +13.6% vs FY 2020 Q3
FY 2021 Q1$505M; −11.2% vs FY 2020 Q4
FY 2021 Q2$595.1M; +17.8% vs FY 2021 Q1
FY 2021 Q3$650.2M; +9.3% vs FY 2021 Q2
FY 2021 Q4$698.2M; +7.4% vs FY 2021 Q3
FY 2022 Q1$628.8M; −9.9% vs FY 2021 Q4
FY 2022 Q2$696.2M; +10.7% vs FY 2022 Q1
FY 2022 Q3$769.6M; +10.5% vs FY 2022 Q2
FY 2022 Q4$815.2M; +5.9% vs FY 2022 Q3
FY 2023 Q1$741.5M; −9.0% vs FY 2022 Q4
FY 2023 Q2$871.3M; +17.5% vs FY 2023 Q1
FY 2023 Q3$975M; +11.9% vs FY 2023 Q2
FY 2023 Q4$1,034.5M; +6.1% vs FY 2023 Q3
FY 2024 Q1$921M; −11.0% vs FY 2023 Q4
FY 2024 Q2$1,004.3M; +9.0% vs FY 2024 Q1
FY 2024 Q3$994.2M; −1.0% vs FY 2024 Q2
FY 2024 Q4$1,113.5M; +12.0% vs FY 2024 Q3
FY 2025 Q1$1,036M; −7.0% vs FY 2024 Q4
FY 2025 Q2$1,157.1M; +11.7% vs FY 2025 Q1
FY 2025 Q3$1,209.3M; +4.5% vs FY 2025 Q2
FY 2025 Q4$1,259.6M; +4.2% vs FY 2025 Q3
FY 2026 Q1$1,191.9M; −5.4% vs FY 2025 Q4
FY 2026 Q2$1,308.4M; +9.8% vs FY 2026 Q1
Jun 30, 2011 through Sep 25, 2026

Free cash flow

USD millions

$184.5M
Dexcom Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2011 Q2$-3.686M; Change unavailable vs FY 2011 Q1
FY 2011 Q3$-8.247M; −123.7% vs FY 2011 Q2
FY 2011 Q4$-15.119M; −83.3% vs FY 2011 Q3
FY 2012 Q1$-12.484M; +17.4% vs FY 2011 Q4
FY 2012 Q2$-9.211M; +26.2% vs FY 2012 Q1
FY 2012 Q3$-8.944M; +2.9% vs FY 2012 Q2
FY 2012 Q4$-11.961M; −33.7% vs FY 2012 Q3
FY 2013 Q1$-5.9M; +50.7% vs FY 2012 Q4
FY 2013 Q2$-1.1M; +81.4% vs FY 2013 Q1
FY 2013 Q3$-0.6M; +45.5% vs FY 2013 Q2
FY 2013 Q4$2.1M; +450.0% vs FY 2013 Q3
FY 2014 Q1$-6.3M; −400.0% vs FY 2013 Q4
FY 2014 Q2$2.2M; +134.9% vs FY 2014 Q1
FY 2014 Q3$7.7M; +250.0% vs FY 2014 Q2
FY 2014 Q4$3.8M; −50.6% vs FY 2014 Q3
FY 2015 Q1$-4.6M; −221.1% vs FY 2014 Q4
FY 2015 Q2$10.1M; +319.6% vs FY 2015 Q1
FY 2015 Q3$10.5M; +4.0% vs FY 2015 Q2
FY 2015 Q4$-0.3M; −102.9% vs FY 2015 Q3
FY 2016 Q1$-11.7M; −3800.0% vs FY 2015 Q4
FY 2016 Q2$9.6M; +182.1% vs FY 2016 Q1
FY 2016 Q3$6.9M; −28.1% vs FY 2016 Q2
FY 2016 Q4$-4.3M; −162.3% vs FY 2016 Q3
FY 2017 Q1$-22.6M; −425.6% vs FY 2016 Q4
FY 2017 Q2$2.3M; +110.2% vs FY 2017 Q1
FY 2017 Q3$22.7M; +887.0% vs FY 2017 Q2
FY 2017 Q4$23.6M; +4.0% vs FY 2017 Q3
FY 2018 Q1$-24M; −201.7% vs FY 2017 Q4
FY 2018 Q2$31.1M; +229.6% vs FY 2018 Q1
FY 2018 Q3$33M; +6.1% vs FY 2018 Q2
FY 2018 Q4$16M; −51.5% vs FY 2018 Q3
FY 2019 Q1$-27.5M; −271.9% vs FY 2018 Q4
FY 2019 Q2$17.6M; +164.0% vs FY 2019 Q1
FY 2019 Q3$44.8M; +154.5% vs FY 2019 Q2
FY 2019 Q4$99.6M; +122.3% vs FY 2019 Q3
FY 2020 Q1$-31.3M; −131.4% vs FY 2019 Q4
FY 2020 Q2$95.9M; +406.4% vs FY 2020 Q1
FY 2020 Q3$100.2M; +4.5% vs FY 2020 Q2
FY 2020 Q4$111.8M; +11.6% vs FY 2020 Q3
FY 2021 Q1$-71.9M; −164.3% vs FY 2020 Q4
FY 2021 Q2$-39.6M; +44.9% vs FY 2021 Q1
FY 2021 Q3$139.2M; +451.5% vs FY 2021 Q2
FY 2021 Q4$25.6M; −81.6% vs FY 2021 Q3
FY 2022 Q1$-30.6M; −219.5% vs FY 2021 Q4
FY 2022 Q2$81.3M; +365.7% vs FY 2022 Q1
FY 2022 Q3$185M; +127.6% vs FY 2022 Q2
FY 2022 Q4$69M; −62.7% vs FY 2022 Q3
FY 2023 Q1$80.7M; +17.0% vs FY 2022 Q4
FY 2023 Q2$131.3M; +62.7% vs FY 2023 Q1
FY 2023 Q3$218.8M; +66.6% vs FY 2023 Q2
FY 2023 Q4$81.1M; −62.9% vs FY 2023 Q3
FY 2024 Q1$152.3M; +87.8% vs FY 2023 Q4
FY 2024 Q2$213.3M; +40.1% vs FY 2024 Q1
FY 2024 Q3$88.3M; −58.6% vs FY 2024 Q2
FY 2024 Q4$176.8M; +100.2% vs FY 2024 Q3
FY 2025 Q1$96.8M; −45.2% vs FY 2024 Q4
FY 2025 Q2$208.9M; +115.8% vs FY 2025 Q1
FY 2025 Q3$579.4M; +177.4% vs FY 2025 Q2
FY 2025 Q4$192.1M; −66.8% vs FY 2025 Q3
FY 2026 Q1$449M; +133.7% vs FY 2025 Q4
FY 2026 Q2$184.5M; −58.9% vs FY 2026 Q1

Net margin

%

19.04%
Dexcom Net margin. Reported fiscal history.
Fiscal period%
FY 2011 Q2-34.4%
FY 2011 Q3-72.74%
FY 2011 Q4-54.64%
FY 2012 Q1-69.99%
FY 2012 Q2-62.65%
FY 2012 Q3-74.77%
FY 2012 Q4-25.53%
FY 2013 Q1-37.5%
FY 2013 Q2-28.21%
FY 2013 Q3-13.99%
FY 2013 Q4-5.03%
FY 2014 Q1-26.54%
FY 2014 Q2-10.2%
FY 2014 Q3-7.54%
FY 2014 Q41.54%
FY 2015 Q1-17.72%
FY 2015 Q2-3.97%
FY 2015 Q3-40.4%
FY 2015 Q41.15%
FY 2016 Q1-16.52%
FY 2016 Q2-14.71%
FY 2016 Q3-12.65%
FY 2016 Q4-4.32%
FY 2017 Q1-29.3%
FY 2017 Q21.7%
FY 2017 Q3-1.08%
FY 2017 Q4-4.25%
FY 2018 Q1-13.12%
FY 2018 Q212.45%
FY 2018 Q317.47%
FY 2018 Q4-53.17%
FY 2019 Q1-9.59%
FY 2019 Q2-3.12%
FY 2019 Q311.56%
FY 2019 Q420.03%
FY 2020 Q14.91%
FY 2020 Q210.25%
FY 2020 Q314.41%
FY 2020 Q462.44%
FY 2021 Q17.98%
FY 2021 Q210.57%
FY 2021 Q310.9%
FY 2021 Q4-2.78%
FY 2022 Q115.47%
FY 2022 Q27.31%
FY 2022 Q313.15%
FY 2022 Q411.26%
FY 2023 Q16.55%
FY 2023 Q213.3%
FY 2023 Q312.38%
FY 2023 Q424.78%
FY 2024 Q115.9%
FY 2024 Q214.29%
FY 2024 Q313.54%
FY 2024 Q413.62%
FY 2025 Q110.17%
FY 2025 Q215.54%
FY 2025 Q323.47%
FY 2025 Q421.22%
FY 2026 Q116.74%
FY 2026 Q219.04%

P/E

× · TTM · Daily

33.8×
Dexcom P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2015-02-27—2013-09-30
2015-03-31—2013-09-30
2015-04-30—2013-09-30
2015-05-29—2013-09-30
2015-06-30—2013-09-30
2015-07-31—2013-09-30
2015-08-31—2013-09-30
2015-09-30—2013-09-30
2015-10-30—2013-09-30
2015-11-30—2013-09-30
2015-12-31—2013-09-30
2016-01-29—2013-09-30
2016-02-29—2014-09-30
2016-03-31—2014-09-30
2016-04-29—2014-09-30
2016-05-31—2014-09-30
2016-06-30—2014-09-30
2016-07-29—2014-09-30
2016-08-31—2014-09-30
2016-09-30—2014-09-30
2016-10-31—2014-09-30
2016-11-30—2014-09-30
2016-12-30—2014-09-30
2017-01-31—2014-09-30
2017-02-28—2014-09-30
2017-03-31—2015-09-30
2017-04-28—2015-09-30
2017-05-31—2015-09-30
2017-06-30—2015-09-30
2017-07-31—2015-09-30
2017-08-31—2017-06-30
2017-09-29—2017-06-30
2017-10-31—2017-06-30
2017-11-30—2017-06-30
2017-12-29—2017-06-30
2018-01-31—2017-06-30
2018-02-28—2017-06-30
2018-03-29—2017-06-30
2018-04-30—2017-06-30
2018-05-31—2017-06-30
2018-06-29—2017-06-30
2018-07-31—2017-06-30
2018-08-31—2017-06-30
2018-09-28—2017-06-30
2018-10-31—2017-06-30
2018-11-30—2017-09-30
2018-12-31—2017-09-30
2019-01-31—2017-09-30
2019-02-28291.24×2018-09-30
2019-03-29248.95×2018-09-30
2019-04-30253.07×2018-09-30
2019-05-31253.55×2018-09-30
2019-06-28313.21×2018-09-30
2019-07-31327.9×2018-09-30
2019-08-30—2019-06-30
2019-09-30—2019-06-30
2019-10-31—2019-06-30
2019-11-29—2019-09-30
2019-12-31—2019-09-30
2020-01-31—2019-09-30
2020-02-28—2019-09-30
2020-03-31—2019-09-30
2020-04-30213.27×2020-03-31
2020-05-29240.7×2020-03-31
2020-06-30257.93×2020-03-31
2020-07-31206.39×2020-06-30
2020-08-31201.59×2020-06-30
2020-09-30195.34×2020-06-30
2020-10-30137.6×2020-09-30
2020-11-30137.64×2020-09-30
2020-12-31159.18×2020-09-30
2021-01-29161.39×2020-09-30
2021-02-26171.26×2020-09-30
2021-03-31154.74×2020-09-30
2021-04-30166.24×2020-09-30
2021-05-28159.04×2020-09-30
2021-06-30183.84×2020-09-30
2021-07-30221.95×2020-09-30
2021-08-31227.94×2020-09-30
2021-09-30235.45×2020-09-30
2021-10-29268.32×2020-09-30
2021-11-30242.22×2020-09-30
2021-12-31231.18×2020-09-30
2022-01-31185.34×2020-09-30
2022-02-28178.21×2020-09-30
2022-03-31220.27×2020-09-30
2022-04-29175.91×2020-09-30
2022-05-31128.28×2020-09-30
2022-06-30128.36×2020-09-30
2022-07-29141.36×2020-09-30
2022-08-31141.58×2020-09-30
2022-09-30138.71×2020-09-30
2022-10-31208.01×2020-09-30
2022-11-30200.26×2020-09-30
2022-12-30195.02×2020-09-30
2023-01-31184.43×2020-09-30
2023-02-28138.61×2022-12-31
2023-03-31145.06×2022-12-31
2023-04-28173.61×2023-03-31
2023-05-31167.77×2023-03-31
2023-06-30183.87×2023-03-31
2023-07-31150.34×2023-06-30
2023-08-31121.88×2023-06-30
2023-09-29112.61×2023-06-30
2023-10-31100.56×2023-09-30
2023-11-30130.78×2023-09-30
2023-12-29140.48×2023-09-30
2024-01-31137.38×2023-09-30
2024-02-2988.65×2023-12-31
2024-03-28106.86×2023-12-31
2024-04-3083.03×2024-03-31
2024-05-3177.42×2024-03-31
2024-06-2873.9×2024-03-31
2024-07-3144.21×2024-03-31
2024-08-3045.2×2024-03-31
2024-09-3043.7×2024-03-31
2024-10-3145.94×2024-03-31
2024-11-2950.83×2024-03-31
2024-12-3150.69×2024-03-31
2025-01-3156.6×2024-03-31
2025-02-2862.38×2024-12-31
2025-03-3148.21×2024-12-31
2025-04-3050.39×2024-12-31
2025-05-3060.57×2024-12-31
2025-06-3061.62×2024-12-31
2025-07-3157.02×2024-12-31
2025-08-2953.18×2024-12-31
2025-09-3047.5×2024-12-31
2025-10-3132.91×2025-09-30
2025-11-2835.88×2025-09-30
2025-12-3137.52×2025-09-30
2026-01-3041.29×2025-09-30
2026-02-2735.03×2025-12-31
2026-03-3129.96×2025-12-31
2026-04-3028.41×2025-12-31
2026-05-2931.2×2026-03-31
2026-06-3028.49×2026-03-31
2026-07-3132.56×2026-06-30
2026-08-3135.53×2026-06-30
2026-09-2533.8×2026-06-30
Mean 135.67×Median 142.1×76% below median

ROIC

% · Annual / TTM

—
Reported borrowing balances are unavailable in the extracted statements for this period.
Dexcom ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q4—
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q4—
FY 2018 Q1—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q4—
FY 2022 Q1—
FY 2022 Q2—
FY 2022 Q3—
FY 2022 Q4—
FY 2023 Q1—
FY 2023 Q2—
FY 2023 Q3—
FY 2023 Q4—
FY 2024 Q1—
FY 2024 Q2—
FY 2024 Q3—
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q4—
FY 2026 Q1—
FY 2026 Q2—

Capital allocation

% of tracked cash uses

$84.7M
Dexcom capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2011 Q2100% · $1.16MUnavailableUnavailableUnavailableUnavailable100% · $1.16M
FY 2011 Q3100% · $1.506MUnavailableUnavailableUnavailableUnavailable100% · $1.506M
FY 2011 Q4100% · $3.549MUnavailableUnavailableUnavailableUnavailable100% · $3.549M
FY 2012 Q1100% · $2.32MUnavailableUnavailableUnavailableUnavailable100% · $2.32M
FY 2012 Q2100% · $2.882MUnavailableUnavailableUnavailableUnavailable100% · $2.882M
FY 2012 Q3100% · $2.894MUnavailableUnavailableUnavailableUnavailable100% · $2.894M
FY 2012 Q4100% · $1.404MUnavailableUnavailableUnavailableUnavailable100% · $1.404M
FY 2013 Q1100% · $1.4MUnavailableUnavailableUnavailable0% · $0M100% · $1.4M
FY 2013 Q2100% · $2MUnavailableUnavailableUnavailable0% · $0M100% · $2M
FY 2013 Q3100% · $2.2MUnavailableUnavailableUnavailable0% · $0M100% · $2.2M
FY 2013 Q492% · $2.3MUnavailableUnavailableUnavailable8% · $0.2M100% · $2.5M
FY 2014 Q188.64% · $3.9MUnavailableUnavailableUnavailable11.36% · $0.5M100% · $4.4M
FY 2014 Q286.96% · $4MUnavailableUnavailableUnavailable13.04% · $0.6M100% · $4.6M
FY 2014 Q388.1% · $3.7M0% · $0MUnavailableUnavailable11.9% · $0.5M100% · $4.2M
FY 2014 Q488.46% · $4.6M0% · $0MUnavailableUnavailable11.54% · $0.6M100% · $5.2M
FY 2015 Q193.02% · $8MUnavailableUnavailableUnavailable6.98% · $0.6M100% · $8.6M
FY 2015 Q291.3% · $6.3MUnavailableUnavailableUnavailable8.7% · $0.6M100% · $6.9M
FY 2015 Q393.67% · $7.4M0% · $0MUnavailableUnavailable6.33% · $0.5M100% · $7.9M
FY 2015 Q495.08% · $11.6M0% · $0MUnavailableUnavailable4.92% · $0.6M100% · $12.2M
FY 2016 Q195.04% · $11.5MUnavailableUnavailableUnavailable4.96% · $0.6M100% · $12.1M
FY 2016 Q286.07% · $10.5MUnavailableUnavailableUnavailable13.93% · $1.7M100% · $12.2M
FY 2016 Q3100% · $16.1MUnavailableUnavailableUnavailable0% · $0M100% · $16.1M
FY 2016 Q4100% · $17.6MUnavailableUnavailableUnavailable0% · $0M100% · $17.6M
FY 2017 Q1100% · $22.9MUnavailableUnavailableUnavailable0% · $0M100% · $22.9M
FY 2017 Q2100% · $12MUnavailableUnavailableUnavailable0% · $0M100% · $12M
FY 2017 Q3100% · $13.5MUnavailableUnavailableUnavailable0% · $0M100% · $13.5M
FY 2017 Q4100% · $17.6M0% · $0MUnavailableUnavailable0% · $0M100% · $17.6M
FY 2018 Q1100% · $15.3MUnavailableUnavailableUnavailableUnavailable100% · $15.3M
FY 2018 Q2100% · $10.3MUnavailableUnavailableUnavailableUnavailable100% · $10.3M
FY 2018 Q3100% · $23.8MUnavailableUnavailableUnavailableUnavailable100% · $23.8M
FY 2018 Q4100% · $17.7M0% · $0MUnavailableUnavailableUnavailable100% · $17.7M
FY 2019 Q1100% · $39.3MUnavailableUnavailableUnavailableUnavailable100% · $39.3M
FY 2019 Q2100% · $46.9MUnavailableUnavailableUnavailableUnavailable100% · $46.9M
FY 2019 Q3100% · $49.7MUnavailableUnavailableUnavailableUnavailable100% · $49.7M
FY 2019 Q4100% · $44.1M0% · $0MUnavailableUnavailableUnavailable100% · $44.1M
FY 2020 Q1100% · $33.2MUnavailableUnavailableUnavailableUnavailable100% · $33.2M
FY 2020 Q2100% · $58.2MUnavailableUnavailableUnavailableUnavailable100% · $58.2M
FY 2020 Q3100% · $47.4MUnavailableUnavailableUnavailableUnavailable100% · $47.4M
FY 2020 Q4100% · $60.2M0% · $0MUnavailableUnavailableUnavailable100% · $60.2M
FY 2021 Q1100% · $99.7M0% · $0MUnavailableUnavailableUnavailable100% · $99.7M
FY 2021 Q2100% · $101.2M0% · $0MUnavailableUnavailableUnavailable100% · $101.2M
FY 2021 Q377.38% · $108.1M22.62% · $31.6MUnavailableUnavailableUnavailable100% · $139.7M
FY 2021 Q4100% · $80.2MUnavailable0% · $0MUnavailableUnavailable100% · $80.2M
FY 2022 Q196.95% · $101.6M3.05% · $3.2MUnavailableUnavailableUnavailable100% · $104.8M
FY 2022 Q2100% · $91.5M0% · $0MUnavailableUnavailableUnavailable100% · $91.5M
FY 2022 Q316.23% · $108.2M0.11% · $0.7M83.66% · $557.7MUnavailableUnavailable100% · $666.6M
FY 2022 Q4100% · $63.5M0% · $0M0% · $0MUnavailable0% · $0M100% · $63.5M
FY 2023 Q1100% · $74.7M0% · $0MUnavailableUnavailableUnavailable100% · $74.7M
FY 2023 Q2100% · $59M0% · $0MUnavailableUnavailableUnavailable100% · $59M
FY 2023 Q3100% · $50.4M0% · $0M0% · $0MUnavailableUnavailable100% · $50.4M
FY 2023 Q47.62% · $52.5M0% · $0M72.54% · $500MUnavailable19.85% · $136.8M100% · $689.3M
FY 2024 Q1100% · $56.9MUnavailableUnavailableUnavailableUnavailable100% · $56.9M
FY 2024 Q2100% · $66.1MUnavailableUnavailableUnavailableUnavailable100% · $66.1M
FY 2024 Q312.91% · $111.2MUnavailable87.09% · $750MUnavailableUnavailable100% · $861.2M
FY 2024 Q4100% · $124.6MUnavailable0% · $0MUnavailable0% · $0M100% · $124.6M
FY 2025 Q1100% · $87MUnavailableUnavailableUnavailableUnavailable100% · $87M
FY 2025 Q2100% · $94.1MUnavailableUnavailableUnavailableUnavailable100% · $94.1M
FY 2025 Q330.07% · $80.5MUnavailable69.93% · $187.2MUnavailableUnavailable100% · $267.7M
FY 2025 Q424.57% · $101.9MUnavailable75.43% · $312.8MUnavailableUnavailable100% · $414.7M
FY 2026 Q1100% · $76.6MUnavailableUnavailableUnavailableUnavailable100% · $76.6M
FY 2026 Q2100% · $84.7MUnavailableUnavailableUnavailableUnavailable100% · $84.7M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Dexcom.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources